{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T19:30:15Z","timestamp":1781379015741,"version":"3.54.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.biopha.2024.116719","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T02:50:05Z","timestamp":1715741405000},"page":"116719","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Evaluation of BH3 mimetics as a combination therapy with irradiation in head and neck squamous cell carcinoma"],"prefix":"10.1016","volume":"175","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3330-1670","authenticated-orcid":false,"given":"Katja","family":"Korelin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayke","family":"Oostveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafa","family":"Wahbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipp","family":"Ianevski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Cavalcante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Turunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2190-4909","authenticated-orcid":false,"given":"Ilya","family":"Belevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Al-Samadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuula","family":"Salo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.116719_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2024.116719_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2024.116719_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.00041","article-title":"Molecular mechanisms of radiation-induced cancer cell death: a primer","author":"Sia","year":"2020","journal-title":"Front Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2024.116719_bib4","first-page":"65","article-title":"BCL-2 family proteins: changing partners in the dance towards death","volume":"125","author":"Kale","year":"2017","journal-title":"Cell Death Differ. 2018 25"},{"key":"10.1016\/j.biopha.2024.116719_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2022.105979","article-title":"Anticancer effects of putative and validated BH3-mimetic drugs in head and neck squamous cell carcinomas: An overview of current knowledge","volume":"132","author":"Melo","year":"2022","journal-title":"Oral. Oncol."},{"key":"10.1016\/j.biopha.2024.116719_bib6","doi-asserted-by":"crossref","unstructured":"J.C. Pena, C.B. Thompson, W. Recant, E.E. Vokes, C.M. Rudin, 1999, , Bcl-x L and Bcl-2 Expression in Squamous Cell Carcinoma of the Head and Neck\u200b10.1002\/(SICI)1097-0142(19990101)85:1.","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<164::AID-CNCR23>3.0.CO;2-Q"},{"issue":"10","key":"10.1016\/j.biopha.2024.116719_bib7","first-page":"1","article-title":"Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck","volume":"12","author":"Carter","year":"2019","journal-title":"Cell Death Dis. 2019 10"},{"key":"10.1016\/j.biopha.2024.116719_bib8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3233\/CBM-182106","article-title":"The association of Bcl-xL and p53 expression with survival outcomes in oropharyngeal cancer","volume":"24","author":"Ziai","year":"2019","journal-title":"Cancer Biomark."},{"key":"10.1016\/j.biopha.2024.116719_bib9","first-page":"7360","article-title":"Bcl-xL overexpression and its association with the progress of tongue carcinoma","volume":"7","author":"Zhang","year":"2014","journal-title":"Int J. Clin. Exp. Pathol."},{"key":"10.1016\/j.biopha.2024.116719_bib10","unstructured":"FDA approves venetoclax for CLL and SLL | FDA. \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-venetoclax-cll-and-sll\u3009. Accessed 6 Jun 2023."},{"key":"10.1016\/j.biopha.2024.116719_bib11","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.3389\/fphar.2020.564108","article-title":"Clinical review: navitoclax as a pro-apoptotic and anti-fibrotic agent","volume":"11","author":"Mohamad Anuar","year":"2020","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2024.116719_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94259-5","article-title":"High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma","author":"Tuomainen","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.116719_bib13","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/molpharm.121.000354","article-title":"Senolytic-mediated elimination of head and neck tumor cells induced into senescence by cisplatin","volume":"101","author":"Ahmadinejad","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2024.116719_bib14","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1006\/excr.1996.0215","article-title":"HPV immortalization of human oral epithelial cells: a model for carcinogenesis","volume":"226","author":"Oda","year":"1996","journal-title":"Exp. Cell Res"},{"key":"10.1016\/j.biopha.2024.116719_bib15","first-page":"1013","article-title":"Isolation and characterization of myofibroblast cell lines from oral squamous cell carcinoma","volume":"25","author":"Sobral","year":"2011","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.biopha.2024.116719_bib16","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/ijc.25358","article-title":"Cancer-associated fibroblasts and epithelial-mesenchymal transition in metastatic oral tongue squamous cell carcinoma","volume":"127","author":"Vered","year":"2010","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.biopha.2024.116719_bib17","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","article-title":"Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia","volume":"3","author":"Pemovska","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2024.116719_bib18","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2016.0482","article-title":"Organotypic three-dimensional assays based on human leiomyoma\u2013derived matrices","author":"Salo","year":"2018","journal-title":"Philos. Trans. R. Soc. B\u00a0Biol. Sci."},{"key":"10.1016\/j.biopha.2024.116719_bib19","article-title":"Human tumor\u2013derived matrix improves the predictability of head and neck cancer drug testing","author":"Tuomainen","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2024.116719_bib20","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1093\/bioinformatics\/btaa138","article-title":"Breeze: an integrated quality control and data analysis application for high-throughput drug screening","volume":"36","author":"Potdar","year":"2020","journal-title":"Bioinformatics"},{"key":"10.1016\/j.biopha.2024.116719_bib21","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.biopha.2024.116719_bib22","doi-asserted-by":"crossref","DOI":"10.3791\/59567","article-title":"Fully human tumor-based matrix in three-dimensional spheroid invasion assay","author":"Naakka","year":"2019","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.biopha.2024.116719_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002340","article-title":"Microscopy image browser: a platform for segmentation and analysis of multidimensional datasets","volume":"14","author":"Belevich","year":"2016","journal-title":"PLoS Biol."},{"key":"10.1016\/j.biopha.2024.116719_bib24","doi-asserted-by":"crossref","unstructured":"K. He, X. Zhang, S. Ren, J. Sun, 2016, , Deep Residual Learning for Image Recognition10.1109\/CVPR.2016.90.","DOI":"10.1109\/CVPR.2016.90"},{"key":"10.1016\/j.biopha.2024.116719_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1008374","article-title":"DeepMIB: user-friendly and open-source software for training of deep learning network for biological image segmentation","volume":"17","author":"Belevich","year":"2021","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.biopha.2024.116719_bib26","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1021\/acsmedchemlett.9b00568","article-title":"Discovery of A-1331852, a first-in-class, potent, and orally-bioavailable BCL-XL inhibitor","volume":"11","author":"Wang","year":"2020","journal-title":"ACS Med Chem. Lett."},{"issue":"11","key":"10.1016\/j.biopha.2024.116719_bib27","first-page":"9","article-title":"The molecular biology of head and neck cancer","volume":"1","author":"Leemans","year":"2010","journal-title":"Nat. Rev. Cancer 2011 11"},{"issue":"11","key":"10.1016\/j.biopha.2024.116719_bib28","first-page":"1","article-title":"High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma","volume":"1","author":"Tuomainen","year":"2021","journal-title":"Sci. Rep. 2021 11"},{"key":"10.1016\/j.biopha.2024.116719_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23147850","article-title":"Specific targeting of antiapoptotic Bcl-2 proteins as a radiosensitizing approach in solid tumors","author":"Sobol","year":"2022","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.116719_bib30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1021\/ml5001867","article-title":"Discovery of a Potent and Selective BCL-X L inhibitor with in vivo activity","volume":"5","author":"Tao","year":"2014","journal-title":"ACS Med Chem. Lett."},{"issue":"7","key":"10.1016\/j.biopha.2024.116719_bib31","first-page":"1","article-title":"Bcl-xL promotes metastasis independent of its anti-apoptotic activity","volume":"1","author":"Choi","year":"2016","journal-title":"Nat. Commun. 2016 7"},{"key":"10.1016\/j.biopha.2024.116719_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-017-0055-y","article-title":"BCL-XL overexpression promotes tumor progression-associated properties","author":"Trisciuoglio","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2024.116719_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076446","article-title":"Beyond cell death \u2013 antiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitro","volume":"8","author":"Koehler","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2024.116719_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa4642","article-title":"Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy","author":"Leverson","year":"2015","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.biopha.2024.116719_bib35","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2024.116719_bib36","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.trecan.2020.03.012","article-title":"Zebrafish xenografts for drug discovery and personalized medicine","volume":"6","author":"Xiao","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.biopha.2024.116719_bib37","first-page":"127","article-title":"FDA no longer has to require animal testing for new drugs","volume":"379","author":"Wadman","year":"2023","journal-title":"Science (1979)"},{"key":"10.1016\/j.biopha.2024.116719_bib38","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s13402-019-00431-5","article-title":"ABT-263 exhibits apoptosis-inducing potential in oral cancer cells by targeting C\/EBP-homologous protein","volume":"42","author":"Yang","year":"2019","journal-title":"Cell Oncol."},{"key":"10.1016\/j.biopha.2024.116719_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.00033","article-title":"Is it time to start transitioning from 2D to 3D cell culture","author":"Jensen","year":"2020","journal-title":"Front Mol. Biosci."},{"key":"10.1016\/j.biopha.2024.116719_bib40","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/cells12030360","article-title":"Comparison of radiation response between 2D and 3D cell culture models of different human cancer cell lines","volume":"12","author":"Raitanen","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2024.116719_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101677","article-title":"Evaluation of in vitro and in vivo personalized cancer treatment assays for oral squamous cell carcinoma","volume":"33","author":"Wahbi","year":"2023","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.biopha.2024.116719_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2019.11.039","article-title":"Developments in zebrafish avatars as radiotherapy sensitivity reporters - towards personalized medicine","author":"Costa","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.biopha.2024.116719_bib43","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2024.116719_bib44","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1200\/JCO.21.02188","article-title":"Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy","volume":"40","author":"Harrison","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.biopha.2024.116719_bib45","first-page":"1938","article-title":"A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity","volume":"12","author":"Khan","year":"2019","journal-title":"Nat. Med. 2019 25"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224006036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224006036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T19:41:08Z","timestamp":1741030868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224006036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":45,"alternative-id":["S0753332224006036"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116719","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of BH3 mimetics as a combination therapy with irradiation in head and neck squamous cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116719","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116719"}}